A secondary or “sidebar” display within a process control environment may provide several small applications to allow business managers, engineers, maintenance personnel, or other non-operator personnel to organize and manage process control system information and to display selected diagnostics and summary information or “key operating parameters” for the process control system. Further, sidebar applications may communicate with other applications that are executing on a non-operator user's workstation to, thereby, retrieve information related to tasks that the user is currently completing. The sidebar application may then determine whether certain process control information may be useful for the main task the user is completing and display that process control information within the sidebar.

An audio navigation device comprising an input means for inputting two or more audio pieces into the navigation device; a spatialization means for allocating a position in the form of a unique spatial co-ordinate to each audio piece and arranging the audio pieces in a multi-dimensional arrangement; a generating means for generating a binaural audio output for each audio piece, wherein the audio output simulates sounds that would be made by one or more physical sources located at the given position of each audio piece; an output means for simultaneously outputting multiple audio pieces as binaural audio output to a user; a navigation means for enabling a user to navigate around the audio outputs in the multi-dimensional arrangement; a selection means for allowing a user to select a single audio output.

A method models a defect management routine. Both the modeling and a handling are executed within a manufacturing execution system. During an engineering phase: modeling the production process and creating a library of possible defect types which may occur; assigning the defect types to at least one defect group; creating a library of defect specifications; creating a library of defect type specification details; creating at least one runtime defect criteria that is used to link the defect type to a certain production volume; and creating a runtime defect measurement routine that monitors a corrective measure. During a runtime production phase evaluating the product produced; identifying the respective defect type out of the library of defect types; and using the identified defect type to determine a corrective measure, a runtime defect criteria identifying the resource causing the defect type, a production volume, and to run the respective runtime defect management routine.

Apparatus, and an associated method, for generating a trouble ticket related to an IT incident. When an IT incident occurs, a worklog is formed by a reporter that enters information associated with the incident. Successive inputs, made by appropriate personnel, are made to update the status of the incident. A table-of-contents is formed, associated with the collection of entries of information. And, each entry of information is categorized, to identify the entry by an associated category.

There is provided a method for actuating a first key of a keyboard with a tracer finger of a robot. An exemplary method comprises acquiring parameters of the keyboard and determining a position of the first key as a function of the acquired parameters using a model of the keyboard. The exemplary method also comprises guiding the tracer finger of the robot to the determined position of the first key. The exemplary method additionally comprises actuating the first key with the tracer finger of the robot.

A verification and control method for at least one water purification system is described, which includes a step of supplying, by a server embedded with the water purification system, an editing interface comprising a zone for selecting items of exploitation information representing physical quantities associated with the water purification system, a step of selecting, via the first remote browser, at least one item of exploitation information to constitute at least one exploitation interface page, a step of sending a request to access the exploitation page, by a second remote browser, to the server, a step of collecting the value of each physical quantity represented by a selected item of information to constitute the page, and a step of supplying, by the server, the page comprising each collected value.

Activities, actions and events during user performance of physical activity may be detected using various algorithms and templates. Templates may include an arrangement of one or more states that may identify particular event types and timing between events. Templates may be specific to a particular type of activity (e.g., types of sports, drills, events, etc.), user, terrain, time of day and the like.

A work hanging apparatus includes a hanger line continuously conveying hangers each having a hook, a robot that has a hand with which a work having a hole is held and transfers the held work to a hanging location set in the hanger line, a controller controlling a movement of the hand to catch the hook of one of the hangers with the hole of the held work at the hanging location, a hole deviation detector that detects a positional deviation of the hole of the work, an attitude deviation detector that detects an attitudinal deviation of the hanger, and a corrector that corrects the movement of the hand according to the positional and attitudinal deviations.

The present invention relates to lithium salt-containing rare earth halide solutions in aprotic solvents, processes for production thereof and also use thereof.

Methods and compositions for the deposition of a film on a substrate. In general, the disclosed compositions and methods utilize a precursor containing calcium or strontium.

The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease.

A light absorption anisotropic film, wherein content of a liquid crystalline non-colorable low molecular weight compound is 30% by mass or less; and which is obtained by fixing the alignment of a dichroic dye composition comprising at least one type of azo-based dichroic dye having nematic liquid crystallinity; and shows a diffraction peak derived from a periodic structure in a direction parallel to the alignment axis on measurement of X-ray diffraction. The light absorption anisotropic film is high in dichroism.

The present invention relates to an (amide amino alkane) metal compound represented by the formula (1): wherein M represents a metal atom;R1 represents a linear, branched or cyclic alkyl group having 1 to 6 carbon atoms;R2 and R3 may be the same as, or different from each other, and each independently represents a linear or branched alkyl group having 1 to 3 carbon atoms, or R2 and R3 may form a substituted or unsubstituted 5- or 6-membered ring together with the nitrogen atom to which they are bound;Z represents a linear or branched alkylene group having 1 to 10 carbon atoms (a part of which may optionally form a ring); andn represents a number of the ligands, which is equal to the valence of the metal (M), and represents an integer of from 1 to 3; with the proviso that the metal compounds in which M is Li (Lithium), Be (Beryllium), Ge (Germanium) or Nd (Neodymium) are excluded;the metal compounds in which M is Mg (Magnesium) and R1 is methyl group are excluded;the metal compounds in which M is Zn (Zinc) and R1 is methyl group are excluded;the metal compounds in which M is Bi (Bismuth) and R1 is t-butyl group are excluded; andin cases where n is two or greater, two or more ligands may be the same as, or different from each other; and a method of producing a metal-containing thin film using the metal compound.

This invention relates to novel Ln(III) complexes of pybox, and methods of making the same. The present invention also relates to a method of use of pybox as a chelating moiety and sensitizer for Ln(III) ion luminescence. Derivatives of pybox and methods of making the same are also provided.

Disclosed is a spectrofluorimetrically detectable luminescent composition consisting essentially of at least one energy transfer acceptor lanthanide(III) complex having an emission spectrum maximum in the range from 300 to 2000 nanometers and a luminescence-enhancing amount of at least one energy transfer donor selected from the group consisting of a fluorophore, a lumiphore, an organic compound, a salt of an organic ion, a metal ion, a metal ion complex, or a combination thereof. Such energy transfer donor enhances the luminescence of at least one energy transfer acceptor lanthanide(III) complex, with the conditions that the emission spectrum of any energy transfer donor differs from that of its energy transfer acceptor lanthanide(III) complex; and such energy transfer donor can be dissolved to form a unitary solution in a solvent having an evaporation rate at least as great as that of water.

Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.

A liquid-crystal compound denoted by general formula (I) below wherein each of the groups is defined and Dye denotes an azo dye residue denoted by general formula (II) with X and n also being defined. The azo liquid-crystal compound is capable of orientation with a high degree of orientation order.

Porphyrin compounds are provided. The compounds may further comprise a fused polycyclic aromatic hydrocarbon or a fused heterocyclic aromatic. Fused polycyclic aromatic hydrocarbon s and fused heterocyclic aromatics may extend and broaden absorption, and modify the solubility, crystallinity, and film-forming properties of the porphyrin compounds. Additionally, devices comprising porphyrin compounds are also provided. The porphyrin compounds may be used in a donor/acceptor configuration with compounds, such as C60.

Provided is an oligonucleotide containing an azobenzene derivative, represented by Formula (1) or (2) below: (in the formulae, A1 and A2 each independently represent a hydrogen atom, nucleotide or oligonucleotide, B1 and B2 each independently represent a hydroxyl group, nucleotide or oligonucleotide, R11 and R12 each independently represent a C1-20 alkyl group, R21 and R22 each independently represent a hydrogen atom or C1-20 alkyl group, and R13 to R18 and R23 to R28 each independently represent a hydrogen atom; a C1-20 alkyl group or alkoxy group optionally substituted with a halogen atom, hydroxyl group, amino group, nitro group or carboxyl group; a C2-20 alkenyl group or alkynyl group optionally substituted with a halogen atom, hydroxyl group, amino group, nitro group or carboxyl group; a hydroxyl group; a halogen atom; an amino group; a nitro group; or a carboxyl group).

The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.

A method for removing radioactive contaminants from a given surface. An acidic solution having a pH of less than 3.0, and preferably less than 1.5, of a complex substituted keto-amine, and a mixture of a saturated and unsaturated lower alcohol (e.g. isopropyl alcohol and propargyl alcohol), and concentrated acid is applied to a contaminated surface. The solution is left on said surface for a time sufficient to remove the radioactive contaminants into the acidic solution and then removed. The acidic solution containing the radioactive contaminants is preferably neuralized by an alkaline material to a pH of between 5.5 and 9.0. Removal of thorium contamination from railcars is one useful application of the invention. The method of the present invention has the effect of removing substantially all of the radioactive contaminants from a previously contaminated surface.

A method for removing radioactive contaminants from a given surface. An aqueous solution having a wetting agent and a complex substituted keto-amine is provided. The solution is left on the surface for a time sufficient to remove the radioactive contaminants into the aqueous solution which is then removed. Depending on the type and condition of the surface, a concentrated acid may be added to the aqueous solution to aid in the contaminant removal process. In such a case, a pH of less than 3.0, and preferably less than 1.5 is maintained. If a concentrated acid is used, the acidic solution containing radioactive contaminants is preferably neutralized by an alkaline material to a pH of between 5.5 and 9.0. Removal of thorium contamination from railcars is one useful application of the invention. The method of the present invention has the effect of removing substantially all of the radioactive contaminants from a previously contaminated surface.

A method for removing a wide variety of radioactive contaminants from a contaminated surface sufficient for the surface to be classified as a low-level waste or as free release. Contaminated surfaces may be classified as Class C, Class B, Class A, or high-level radioactive wastes prior to treatment. An aqueous solution having a wetting agent and a complex substituted keto-amine is provided. The aqueous solution is left on the surface for a time sufficient to remove the radioactive contaminants into the aqueous solution which is then removed. Depending on the type and condition of the surface, an acid may be added to the aqueous solution to aid in the contaminant removal process. However, typical metals surfaces may often be treated effectively without the use of concentrated acids or with dilute concentrations of such acids. The method of the present invention has the effect of removing substantially all of the radioactive contaminants from a variety of previously contaminated surfaces.

The present invention concerns a process for dissolving ruthenium deposits that are present on a surface and a process for decontaminating the internal circuits of nuclear fuel reprocessing plants using the said dissolution process. The process according to the invention comprises bringing the said surface into contact with an aqueous solution of perruthenate, with the said aqueous solution having a pH equal to or greater than 12, so that the ruthenium is oxidised.

A radioactive substance decontamination method and apparatus which decontaminates a metal member contaminated by radioactive substance in a short period of time. This apparatus has (1) multiple reducing decontamination tanks having different radiation control values; (2) a carrier for immersing the metal member into the multiple reducing decontamination tanks and a washing tank; (3) a tube for transferring into the second reducing decontamination tank the reducing decontamination agent in the first reducing decontamination tank; (4) a reducing agent decomposer for decomposing a component contained in the reducing decontamination agent of the reducing decontamination tank where the radiation control value is the highest out of the reducing decontamination tanks connected by the tube; and (5) a washing tank for washing the reducing decontamination agent deposited on the decontaminated metal member.

In a chemical decontamination method of chemically decontaminating radioactive nuclides from a metallic material, oxalic acid and hydrazine are injected as a reductive decontaminating agent into water that is in contact with the metallic material. Injection of the hydrazine is stopped after a cation resin arranged in a circulation line connected to the metallic material breaks, and at least the oxalic acid and the hydrazine in the reductive decontaminating agent are decomposed using a decomposing catalyst.

A method for chemically decontaminating radioactive material. The method includes reducing-dissolving step for setting surface of radioactive material in contact with reducing decontamination liquid including mono-carboxylic acid and di-carboxylic acid as dissolvent; and oxidizing-dissolving step for setting the surface of the radioactive material in contact with oxidizing decontamination liquid including oxidizer. The method may include repeated pairs of steps, each pair including the reducing-dissolving step and the oxidizing-dissolving step. The mono-carboxylic acid may include formic acid, and the di-carboxylic acid includes oxalic acid. The oxidizer may be ozone, permanganic acid or permanganate.

A device for inspecting submersed plant parts is particularly suited for ultrasonic inspection of screws in the core baffle of a nuclear reactor pressure vessel. The device includes a remote-controlled underwater vehicle that is provided at its end face with a carrier that can be pivoted about a pivot axis oriented parallel to the longitudinal central axis of the underwater vehicle, and is provided with a holding device for an inspection head that is arranged on the carrier spaced apart from the pivot axis.

Decontamination of nuclear facilities is necessary to reduce the radiation field during normal operations and decommissioning of complex equipment. In this invention, we discuss gel and foam based diphosphonic acid (HEDPA) chemical solutions that are unique in that these solutions can be applied at room temperature; provide protection to the base metal for continued applications of the equipment; and reduce the final waste form production to one step. The HEDPA gels and foams are formulated with benign chemicals, including various solvents, such as ionic liquids and reducing and complexing agents such as hydroxamic acids, and formaldehyde sulfoxylate. Gel and foam based HEDPA processes allow for decontamination of difficult to reach surfaces that are unmanageable with traditional aqueous process methods. Also, the gel and foam components are optimized to maximize the dissolution rate and assist in the chemical transformation of the gel and foam to a stable waste form.

Disclosed is a separation and receiving apparatus for a spent nuclear fuel rod. The spent nuclear fuel rod is mounted and downwardly transferred by a pin. At this time, a blade peels the hull of the spent nuclear fuel rod. The hull and a pellet positioned therein are separated by a separator. The peeled hull and pellet are each received in respective receiving vessels. Accordingly, since the hull and pellet made of uranium oxide (UO2) may be automatically separated and received in each respective vessel, safety and automation may be guaranteed.

The flexible glove holder (1) includes a flat structure (13) with three branches (2, 3 and 4) forming an S-shape on which the glove is wound. The holder (1) is then pushed into the opening of the glove box. This rapid action method makes it possible to avoid knotting the gloves when they must be drawn toward the outside for an operation within the box and also allows the implementation of biological protection on the opening of the glove box as well as a protection of the agents against radiation.

A method for recovery of residual actinide element from chloride molten salts that are formed after electro-refining and/or electro-winning of a spent nuclear fuel and include actinide elements and rare-earth elements is provided. The method comprises conducting electrolysis using a liquid cadmium cathode (LCC) in the chloride molten salt that is formed after electro-refining and/or electro-winning of a spent nuclear fuel and contains rare-earth elements and actinide elements; electro-depositing the actinide elements contained in the chloride molten salt on the LCC in order to reduce a concentration of the actinide elements; and adding a CdCl2 oxidant to the chloride molten salt containing the LCC-metal alloy in order to oxidize the rare-earth elements co-deposited on the LCC, thereby forming the rare-earth chlorides in the chloride molten salt.

A method for design of a fuel assembly for nuclear reactors, including structural components made from zirconium alloy: the mean uniaxial tensile or compressive stress to which the components are subjected during the assembly life is calculated, the zirconium alloy of which the components are made is selected according to the following criteria: those components subjected to an axial or transverse compressive stress of between −10 et −20 MPa are made from an alloy with a content of Sn between Sn=(=0.025σ−0.25)% and Sn=−0.05σ%: those components subjected to such a stress of between 0 et −10 MPa are made from an alloy the Sn content of which is between Sn=traces and Sn=(0.05σ+1)%: those components subjected to such a stress of between 0 and +10 MPa are made from an alloy the Sn content of which is between Sn=0.05% and Sn=(0.07σ+1)%: and those components subjected to such a stress of between +10 and +20 MPa are made from an alloy the content of SN of which is between 0.05% and 1.70%. A fuel assembly made according to the method.

A method for measuring the neutron flux in the core of a nuclear reactor, the method including several steps recurrently performed at instants separated by a period, the method comprising at each given instant the following steps: acquiring a total signal by a cobalt neutron detector placed inside the core of the reactor; assessing a calibration factor representative of the delayed component of the total signal due to the presence of cobalt 60 in the neutron detector; assessing a corrected signal representative of the neutron flux at the detector from the total signal and from the calibration factor; assessing a slope representative of the time-dependent change of the calibration factor between the preceding instant and the given instant; the calibration factor at the given instant being assessed as a function of the calibration factor assessed at the preceding instant, of the slope, and of the time period separating the given instant from the preceding instant.

The invention relates to a polypeptide having a mutation at one or more position corresponding to T219 of SEQ ID NO: 55, wherein the polypeptide has at least 50% sequence identity with SEQ ID NO: 55, and wherein the polypeptide has permease activity.

The invention concerns a soluble pharmaceutical formulation comprising an insulin derivative wherein the formulation further comprises more than 4 zinc atoms per 6 molecules of the insulin derivative, and a citric acid monohydrate and/or a histidine compound used in an amount sufficient to increase the tendency of the insulin derivative to self-associate into dodecamers. The invention further comprises a process for preparing the soluble pharmaceutical formulation.

Provided herein are pharmaceutical formulations containing exendins, exendin agonists, or exendin analog agonists that are administered at therapeutic plasma concentration levels over a sustained period of time to lower total cholesterol levels; to lower LDL-cholesterol levels; to lower triglyceride levels; to treat dyslipidemia; to treat and slow the progression of atherosclerosis; and to treat, prevent, and reduce the risk of heart attacks and strokes in patients. In the pharmaceutical formulations and methods of the invention, the exendin may be exendin-4, an exendin-4 agonist, or an exendin-4 analog agonist. The pharmaceutical formulations may be polymer-based pharmaceutical formulations that may be administered once weekly. An exemplary pharmaceutical formulation comprises 5% (w/w) of exenatide, about 2% (w/w) of sucrose, and about 93% (w/w) of a poly(lactide-co-glycolide) polymer, wherein the poly(lactide-co-glycolide) polymer is in the form of microspheres encapsulating the exenatide.

Cyclic CRF antagonist peptides having improved properties of “drugability”. The peptides are 33 residues in length with a lactam bond between the residues in position 22 and 25; however, they may be N-terminally shortened by up to 3 residues.

To provide a diagnostic and therapeutic medicament, a bombesin analog peptide antagonist conjugate is provided which has general Formula (I), wherein A is a metal chelator comprising at least one radionuclide metal, B is a spacer linked to N-terminal of C or a covalent bond and C is a bombesin analog peptide antagonist having a sequence as claimed, where further x is an integer from 1 to 3 and n is an integer from 1 to 6. [A-(B)n]x—C (I)

A method of producing a molecularly-imprinted material comprises synthesizing a peptide, oligosaccharide or oligonucleotide on a disposable surface modified support to produce a support surface-attached peptide, oligosaccharide or oligonucleotide, providing a selected monomer mixture, contacting the monomer mixture with the support surface-attached peptide, oligosaccharide or oligonucleotide, initiating polymerisation or at least one crosslinking reaction, dissolving or degrading the support surface-attached peptide, oligosaccharide or oligonucleotide and support, and obtaining molecularly imprinted material.

The present invention relates to CX3CR1-binding polypeptides, in particular polypeptides comprising specific immunoglobulin domains. The invention also relates to nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions comprising such polypeptides; and to uses of such polypeptides or such compositions, in particular for prophylactic, therapeutic and diagnostic purposes.

Three conjugation methods for use with the capsular saccharide of Streptococcus agalactiae. In the first method, reductive animation of oxidized sialic acid residue side chains is used, but the aldehyde groups are first aminated, and then the amine is coupled to a carrier via a linker. In the second method, sialic acid residues and/or N-acetyl-glucosamine residues are de-N-acetylated to give amine groups, and the amine groups are coupled to a carrier protein via a linker. In the third method, linkage is via galactose residues in the capsular saccharide rather than sialic acid residues, which can conveniently be achieved using galactose oxidase.

The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.

The present invention relates to gastrin derivatives comprising gastrin or an analogue or fragment thereof and a derivatisation group and therapeutic use thereof.

In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.

The invention relates to melanocortin receptor-specific cyclic peptides of Formula (I) or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4a, R4b, R4c, R5, x and y are as defined in the specification. These compounds are particularly useful in the treatments of energy homeostasis and metabolism related (e.g. diabetes), food intake related and/or energy balance and body weight related diseases, disorders and/or conditions, including obesity, overweight and diseases, disorders and/or conditions associated with obesity and/or overweight, such as type 2 diabetes and metabolic syndrome.

Antigen binding proteins with T cell receptor-like paratopes, that is, with an antigen binding region specific for an human leukocyte antigen-A2 restricted peptide are disclosed. The antigen binding proteins encompass antibodies in a variety of forms, including full-length antibodies, substantially intact antibodies, Fab fragments, F(ab')2 fragments, and single chain Fv fragments. Fusion proteins, such as scFv fusions with immunoglobulin or T-cell receptor domains, incorporating the specificity of the antigen binding region for each peptide are also contemplated by the invention. Furthermore, immunoconjugates may include antibodies to which is linked a radioisotope, fluorescent or other detectable marker, cytotoxin, or other molecule are also encompassed by the invention. Among other things, immunoconjugates can be used for delivery of an agent to elicit a therapeutic effect or to facilitate an immune effector function.

The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.

Monitoring user activity on a mobile device is described. In one aspect, video content is received and played to a user of the mobile device. The monitoring activity detects an interruption of playback of the video content and determines an event associated with the interruption. The event is stored in the mobile device and communicated to a remote device.

A method includes receiving first information identifying profile information associated with a customer, habit information associated with the customer's television viewing habits, or Internet usage information associated with the customer. The method also includes receiving preference information from the customer, wherein the preference information identifies advertisements or types of advertisements that the customer would like to view or would not like to view. The method further includes identifying advertisements based on the received first information and the received preference information, inserting, by a service provider, the identified advertisements in a television programming data stream and providing the identified advertisements to the customer.